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Background Nonalcoholic fatty liver disease (NAFLD) is a chronic liver damage, characterized by fat accumulation in the liver over 5-10% of its weight in the absence of alcohol consumption. Is the most common cause of abnormal liver tests with an increasingly importance due to the association with obesity and T2DM, two major public health problems. In general population the prevalence of NAFLD is 10-24% and increases to 74% at the obese persons [1] . The liver damage ranges from simple steatosis to steatohepatitis with different stages of fibrosis [1] [2] [3] . The etiology of NAFLD is multifactorial, the principal factor being obesity, in particular central obesity but we can also find glycemic disorders: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), diabetes and lipid profile disturbances. The prevalence of obesity in the patients with nonalcoholic fatty liver disease ranges from 30 to 100% [3] and of T2DM from 10-75% [1] . The association of fatty liver with metabolic syndrome suggests that NAFLD can be considered an element of the MS with central disorder of the decrease of insulin sensitivity. An important and common risk factor for liver steatosis is dyslipidemia especially hypertriglyceridemia. In clinical practice hypertriglyceridemic waist refers to the patients with abdominal obesity and high level of triglycerides [4, 5] . Higher level of liver triglycerides production is caused by an excess in glucose and free fatty acids (FFA) in patients with high plasma insulin levels [6] .
Insulin resistance presented in the obese patients can also be found in non-diabetic, non-obese patients with fatty liver accumulation [7] . If insulin resistance is a primary or secondary effect of NAFLD is a subject of debate. Insulin resistance and hyper insulinemia has been considered the link between NAFLD and metabolic syndrome [8, 9, 10] . Is well known that hepatic steatosis is associated with overweight and diabetes [11, 12] , but some patients with NAFLD are normal weight and normal glycemic. The patients with NAFLD have fasting hyper insulinemia independent of weight and fasting plasma glucose [13, 14] . On the other hand, the presence of obesity is not sufficient to predict NAFLD, not all the obese people have fatty liver. "Metabolically-benign" obesity refers to obese patients with normal insulin sensitivity and lower liver fat content [15, 16] . In some cases is a dissociation between fatty liver and insulin resistance. K. Kantartzis et al [17] studied the role of patatin-like phospholipase 3 gene (PNPLA3) in relation with increased liver fat but not with insulin resistance. This suggests a circumstance when the presence of steatosis is not associated with common metabolic disturbances. PNPLA3/adiponutrin increased hepatic triglycerides synthesis, depletion of diacylglycerol and fatty acid content and protect against lipotoxicity.
Metabolic syndrome is present in 60% of females and 30% of males with NAFLD. The presence of metabolic syndrome elements in the patients with NAFLD is associated with a higher risk to progress to NASH independent of sex, age and body mass index [2, 18] . The risk of hepatic steatosis increases exponentially with the addition of each component of the metabolic syndrome. Endothelial dysfunction presented in these patients can explain the increase of cardiovascular risk which is also increased by the aggregation of metabolic elements presented in the patient with fatty liver disease:
hypertension, atherogenic dyslipidemia and coagulation disorders [19, 20] . Spearman's correlation coefficients were calculated in order to test the association between variables. The level for statistical significance was set at p≤0,05.
Material and methods
Results
Depending on sex distribution of the patients we observed a high prevalence of females vs. males: 172 (58.3%) vs 123 (41.7%). According to the presence or absence of NAFLD and MS the cohort was divided in four groups: group 1 -patients with NAFLD and without MS, group 2 -patients with MS and without NAFLD, group 3 -patients with NAFLD and with MS and control grouppatients without NAFLD and without MS ( Table 1 ). The majority of the studied patients was diagnosed with NAFLD and MS.
[NAFLD + MS: 66,1% vs. NAFLD: 16,27% vs. MS: 10,17% vs. nonNAFLD+nonMS: 7,46%; χ 2 270.6; p<0,0001]. The characteristics of the anthropometric and metabolic parameters at the studied groups are showed in Table 2 , represented as mean ± SD.
The mean value of waist circumference in the patients from group 3 was significantly higher than the value recorded in the patients from group 1 and 2. The mean WC in the three studied groups was significantly higher than in the control group. [F=14,7; p<0,0001] (Figure 1 ). BMI value in the patients from group 3 was significantly higher than in group 1 and 2 and higher than BMI of control group [F=20,91; p<0,0001] (Figure 2) . The presence of NAFLD was associated with increased fasting insulin and HOMA-IR more pronounced than with FPG and HbA1c. MS was correlated with FPG and HbA1c and also with higher level of HOMA-IR. The correlation of HOMA-IR with NAFLD was stronger than with MS. The association of NAFLD and MS at the same patient summarized the metabolic consequences related to these disorders: glycemic disorders and decrease of insulin sensitivity. Higher levels of triglycerides and lower for HDLcholesterol were stronger correlated with the presence of MS than with NAFLD. No significantly correlation was found for total cholesterol and LDL-cholesterol values in our studied groups.
NAFLD is associated with an increased cardiovascular risk which is demonstrated by the correlation between NAFLD presence with high values of TC/HDL-cholesterol ratio as a wellknown cardiovascular risk factor and with the presence of hypertension. The correlation coefficients of these associations are lower compared to those obtained for the association between TC/HDL-c ratio and HBP with MS presence. When NAFLD is associated with MS cardiovascular risk is higher. The correlation coefficients of the association between the presence of NAFLD and MS with TC/HDL-c ratio/HBP is over the value obtained for the association between MS and TC/HDL-c ratio/HBP (Table 3) .
Bivariate correlation analysis (Sperman correlation coefficient -r s ) showed the association between the presence of NAFLD/MS and parameters of cardiovascular risk /metabolic disorders. 
Discussions
In this study we evaluated metabolic characteristics of the patients with NAFLD according to the presence of MS and comparing with a control group. The relation of NAFLD with MS is sustained by many sudies which analyzed the correlation of fatty liver with each component of metabolic syndrome. A study on 271 non diabetic subjects demonstrated that liver fat content measured by proton magnetic resonance spectroscopy was 4-fold higher in subjects with than without the metabolic syndrome [21] . The importance of the link between NAFLD and MS is showed in the studies which analyze the clinic and histological changes in the obese patients with hepatic steatosis before and after an important weight reduction made by laparoscopic adjustable gastric band placement. The patients with metabolic syndrome and severely obesity associated with abnormal liver histological features had a major improvement after surgery weight loss or resolution of obesity and metabolic syndrome [22] . The most common conditions associated with NAFLD are obesity and type 2 diabetes [23] . Among the components of metabolic syndrome the best correlation of liver fat was with waist circumference both in women and men [21] . In our study the patients with NAFLD and without MS vs control group had significantly higher values of BMI, WC, FI and HOMA -IR. In the patients with NAFLD and MS, clinic and metabolic disorders were more pronounced. We found a significantly higher level of BMI, WC, triglycerides and a lower level of HDL-c in this group which had a higher level of FPG and HbA1c. Our results are consistent with other studies suggesting that overweight and diabetes magnify fatty infiltration, clinic and biochemical disorders [2] . When NAFLD was associated with the presence of MS, HOMA-IR as a expression of decreased insulin sensitivity was significantly higher. In general practice is important to note that the addition of each component of MS worsened the prognostic of hepatic steatosis. Hellan Kang et al [24] analyzed the differences in histological severity between NAFLD patients with and without MS and showed that the factors associated with high global NASH score were HOMA-IR index and the presence of MS.
It is known that obesity and visceral adiposity are considered risk factors for type 2 diabetes and cardiovascular diseases [25, 26] .
Liver fat content is associated with intraabdominal fat [27, 28] but not with subcutaneous fat (measured with magnetic resonance imaging) [29] . In correlation with visceral adiposity, fatty liver is independent predictor for these diseases. In our data we found a significantly higher prevalence of hypertension (67.7% vs 40.90%) in the patients with NAFLD and MS vs patients from control group [30] . Data reported in other studies showed that insulinresistant state are correlated with cardiovascular risk. NAFLD studied patients had a high level of FI and HOMA-IR index and we can conclude that NAFLD should be considered an indicator of an increased cardiovascular risk, independent of the classical and metabolic syndrome related factors and is part of pathogenetic mechanisms. Also fatty liver has an important role in predicting coronary artery disease. A prospective study made on 612 patients [31] which underwent coronary angiogram showed that 356 (58.2%) had fatty liver after ultrasonography. Coronary artery disease occurred in 84.6% of patients with fatty liver and 64.1% of those without fatty liver. Fatty liver was associated with coronary artery disease in this study independently of age, sex and metabolic factors. The TC/HDLc ratio as a marker of cardiovascular risk was higher at the patients with MS. In the patients with NAFLD this marker was significantly higher only in correlation with the MS elements.
Liver tests (AST, ALT) were significantly elevated in the patients with NAFLD. The increasing of GGT as a predictor for evolution of NAFLD was more pronounced when NAFLD was associated with MS. Liver tests are moderately elevated, especially alanin aminotransferase (ALT), with AST/ALT ratio <1 but in some cases liver tests are normal. The levels of AST/ALT are not always correlated with the stage of hepatic steatosis. Some of the patients with ultrasonographically steatosis even though they have normal alanin aminotransferase levels they can have advanced liver disease. ALT predict the development of type 2 diabetes independent of other factors. The increasing of the liver fat is correlated with ALT value and is part of the pathogenic mechanism of diabetes, independent of the whole body adiposity [32, 33, 34] .
From our study we concluded that the presence of NAFLD was associated with cardiometabolic abnormalities but there are not enough data to demonstrate if NAFLD is a cause or just a marker of the association between metabolic disorders and cardiovascular risk factors. G. Musso et al [16] in a recently meta-analysis showed that in order to evaluate the relation between NAFLD and the developing or deteriorating of type 2 diabetes is necessary to asses not only insulin resistance but also beta cell function which is impaired in the patients with fatty liver. A limitation of our analysis is that HOMA -IR index is easy to be calculated from fasting plasma glucose and fasting insulin values reflects hepatic insulin sensitivity but not skeletal muscle and adipose tissue insulin sensitivity. Many studies reported a correlation of liver disease with adipose tissue insulin sensitivity. It is necessary to extend the number of the studied patients and to assess more information for new data clarification.
